Mylan NV (MYL)

MYL (NASDAQ:Drugs) EQUITY
$40.93
neg -0.38
-0.92%
Today's Range: 40.77 - 41.43 | MYL Avg Daily Volume: 5,769,600
Last Update: 09/28/16 - 11:27 AM EDT
Volume: 866,754
YTD Performance: -23.60%
Open: $41.20
Previous Close: $41.31
52 Week Range: $37.59 - $67.34
Oustanding Shares: 534,911,497
Market Cap: 22,027,655,446
6-Month Chart
TheStreet Ratings Grade for MYL
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 3 3 5 5
Moderate Buy 0 0 0 0
Hold 6 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.33 2.25 2.00 2.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.54%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 25.74
Price Earnings Comparisons:
MYL Sector Avg. S&P 500
25.74 24.20 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-1.20% -5.27% 7.80%
GROWTH 12 Mo 3 Yr CAGR
Revenue 22.10 0.40 0.11
Net Income -9.20 0.30 0.10
EPS -27.00 0.20 0.05
Earnings for MYL:
EBITDA 2.40B
Revenue 9.43B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $1.59 $1.43 $4.93 $5.71
Number of Analysts 7 6 8 8
High Estimate $1.66 $1.48 $5.05 $6.00
Low Estimate $1.53 $1.33 $4.81 $5.44
Prior Year $1.43 $1.22 $4.30 $4.93
Growth Rate (Year over Year) 11.09% 17.21% 14.77% 15.73%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
It appears Twitter will need more than takeover chatter to stay aloft, Oppenheimer analysts say.
Attacking Big Pharma price gougers may be all that unifies the candidates ahead of tonight's debate.
The bear is in control.
And what happened to all those predicting a surprise rate hike?
Wall Street eyes the Fed's decision on interest rates as Mylan's CEO goes to Capital Hill over the EpiPen.
It may not be possible for Valeant to wind down its massive debt as quickly as expected, say Deutsche Bank analysts.
Bayer has agreed to purchase Monsanto for $66 billion, or $128 a share, a 20% premium over its previous closing price.
These stocks look good as seasonal volatility sets in.
Without it, the uncertainty would be incredible between now and November.
Falling crude oil prices continued to weigh on markets Monday.

Columnist Conversations

Decent start to markets today, but then had a quick reversal especially in high beta parts of market.  Bi...
There has been a consistent pattern from the oil markets in the past year. OPEC makes noise about constraining...
yesterday we rolled up a prior play and added an at the money on this momentum name. BOUGHT GWPH NOV 125 CA...
yesterday we added some WDC calls (sorry it's late, i'm still in Chicago and had some internet connection issu...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.